TY - JOUR T1 - Prognostic Markers for Patient Outcome Following Vaccination with Multiple MHC Class I/II-restricted WT1 Peptide-pulsed Dendritic Cells Plus Chemotherapy for Pancreatic Cancer JF - Anticancer Research JO - Anticancer Res SP - 555 LP - 562 VL - 35 IS - 1 AU - KAZUKI TAKAKURA AU - SHIGEO KOIDO AU - SHIN KAN AU - KOSAKU YOSHIDA AU - MASAKO MORI AU - YUTA HIRANO AU - ZENSHO ITO AU - HIROKO KOBAYASHI AU - SHINICHIRO TAKAMI AU - YOSHIHIRO MATSUMOTO AU - MIKIO KAJIHARA AU - TAKEYUKI MISAWA AU - MASATO OKAMOTO AU - HARUO SUGIYAMA AU - SADAMU HOMMA AU - TOSHIFUMI OHKUSA AU - HISAO TAJIRI Y1 - 2015/01/01 UR - http://ar.iiarjournals.org/content/35/1/555.abstract N2 - Background/Aim: Treatment combining dendritic cells (DCs) pulsed with three types of major histocompatibility complex (MHC) class I and II (DC/WT1-I/II)-restricted Wilms' tumor 1 (WT1) peptides with chemotherapy may stabilize disease in pancreatic cancer patients. Materials and Methods: Laboratory data from seven patients with pancreatic cancer who underwent combined DC/WT1-I/II vaccination and chemotherapy were analyzed. The DC phenotypes and plasma cytokine profiles were analyzed via flow cytometry. Results: The post-treatment neutrophil to lymphocyte (N/L) ratio was a treatment-related prognostic factor for better survival. Moreover, the mean fluorescence intensities (MFIs) of human leukocyte antigen (HLA)-DR and cluster of differentiation (CD)83 on DCs were significantly increased after chemoimmunotherapy. Interestingly, interleukin (IL)-6 level in plasma was significantly increased after chemoimmunotherapy in non-super-responders. Conclusion: An increased N/L ratio, as well as HLA-DR and CD83 MFI levels may be prognostic markers of longer survival in patients with advanced pancreatic cancer who undergo chemoimmunotherapy. ER -